Westfuller Advisors’s Haemonetics HAE Stock Holding History

Westfuller Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11	Closed	-$536	–	789
2025 Q3	$536	Buy	+11	New	+$681	﹤0.01%	734

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfuller Advisors's HAE Position: Q4 2025 in Review

Westfuller Advisors sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 11 shares — an estimated $536 sold.

Westfuller Advisors first reported a position in HAE in Q3 2025 and held it in 1 quarter. The position peaked at $536 in Q3 2025. 328 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

Westfuller Advisors reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
Westfuller Advisors sold 11 Haemonetics shares in Q4 2025, an estimated $536.
Westfuller Advisors first reported a position in Haemonetics in Q3 2025 and held it in 1 quarter.
Westfuller Advisors's Haemonetics position peaked at $536 in Q3 2025.
328 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Westfuller Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.